Tracking COVID-19 Vaccines Around the World
In November 2020, the world received the exciting news that the first COVID-19 vaccines were ready for roll out—and as of now, nearly 7.25 billion doses have been pre-purchased by countries and organizations around the globe.
Today’s visualizations highlight the number of vaccine doses that different countries have purchased, as well as the companies and organizations that have pre-sold them.
The data has been collected via the Launch and Scale Speedometer at the Duke Global Health Innovation Center with support from the Bill & Melinda Gates Foundation.
Breaking Down COVID-19 Vaccines by Country
Although high income countries are currently buying the larger shares of doses, India has ordered 1.5 billion—more than any other individual country.
The U.S., in comparison, has pre-purchased 1.01 billion doses, and although this number is less than the amount India has purchased, the U.S. has around 330 million people compared to India’s burgeoning 1.3 billion citizens.
|Country or Region||COVID-19 Vaccine Doses||% Global Share|
|European Union 🇪🇺||1,585,000,000||21.87%|
|Latin America W/O Brazil||150,000,000||2.07%|
|Global Total (as of Dec 11)||7,248,900,075||100.00%|
*COVAX is a global initiative to provide equitable access to COVID-19 vaccines
Without the purchasing power of high income countries, low and middle income countries must leverage other means to acquire COVID-19 vaccines, like volunteering to host clinical trials in exchange for doses, as was done in Peru. India’s ability to purchase so many doses has come out of manufacturing agreements with vaccine producers.
As a percentage of total doses sold, high income countries have bought almost 54%, equating to 4 billion doses. Meanwhile, low and middle income countries have purchased just over 23%.
Notably, Canada has reserved the highest number of doses per person compared to any other country, having ordered over 350 million vaccinations for a population of just over 38 million people, equating to nine doses per person.
The Business of COVID-19 Vaccines
There are currently over 200 vaccine candidates being developed and tested at breakneck speed. However, one important aspect to note is that not all of the vaccine candidates that are being pre-sold will pass the testing stage.
The Oxford University vaccine is the most popular so far, with over 2.5 billion doses sold. The academic institution, together with AstraZeneca, is doling out 500 million vaccines each to India and the U.S., as well as 400 million to the European Union.
Novavax, the second highest seller of COVID-19 vaccines, has pre-sold 1.3 billion doses. So far, the early birds Pfizer-BioNTech and Moderna have pre-sold 10% and 6% of the total vaccine doses being manufactured respectively.
In terms of pricing, Pfizer-BioNTech, for example, is selling their vaccines at $19.50 per dosage. With the current number of doses already sold by Pfizer-BioNTech, that amounts to a current revenue of over $13 billion.
The Way Forward
Without COVID-19 vaccines, health and safety measures such as social distancing and self-isolation would likely stay in place for the foreseeable future.
Looking beyond which countries receive the vaccines first, the World Health Organization has created a road map detailing which individuals should be prioritized, with a focus on frontline healthcare workers and the elderly.
A future where life is somewhat back to normal is on the horizon, but some countries are set to get there faster than others.
The Economic Impact of COVID-19, According to Business Leaders
It’s been a rollercoaster year. Here’s a look at the economic impact of COVID-19 worldwide, according to a survey of global business leaders.
The Economic Impact of COVID-19: Positives and Negatives
The global pandemic has disrupted business activities worldwide. But COVID-19’s economic impact has varied across regions, and the consequences have been largely dependent on a region’s economic position.
Using survey data from the World Economic Forum’s 20th Global Competitiveness Report, this graphic showcases the economic impact of COVID-19 worldwide. This year’s survey was conducted between February and July 2020 and includes responses from 11,866 business executives across 126 economies.
As you’ll see, the data was collected with the specific focus of contrasting the pandemic’s effects on developing economies compared to advanced economies.
Top Negative Impacts of COVID-19
By comparing business leaders’ responses in 2020 to their answers over the last three years, some clear trends have emerged.
In advanced economies, the top negative economic impact of COVID-19 has been a decline in competition, followed by reduced collaboration between companies and a growing challenge in finding and hiring skilled workers:
|Rank||Factor||% Change (2020 vs. 3-Yr Avg)|
|1||Competition in network services||-2.9%|
in professional services
|4||Competition in retail services||-1.8%|
|5||Ease of finding skilled employees||-1.5%|
What’s driving this reduced competition in advanced economies?
One factor could be the increased use of online platforms. Ecommerce is heavily dominated by a select number of retailers. Because of this, bigger retailers like Amazon have seen massive boosts in their online sales, while many smaller brick-and-mortar businesses have been struggling.
While negative impacts on advanced economies are centered around market concentration and talent gaps, developing countries have faced different problems this year, like increased crime and governance issues:
|Rank||Factor||% Change (2020 vs. 3-Yr Avg)|
|1||Business costs of crime and violence||-2.5%|
|4||Extent of market dominance||-0.6%|
|5||Public trust of politicians||-0.4%|
It’s important to note that in the 2018 and 2019 surveys, organized crime and business costs related to crime and violence were trending downward. Because of this, the World Economic Forum suggests that we consider this year’s increase in these areas as as a temporary COVID-induced setback rather than a long-term issue.
Top Positive Impacts of COVID-19
Despite the struggles brought on by COVID-19, the pandemic has also triggered positive change. In fact, business leaders perceived more positive developments this year than negative ones.
In advanced economies, the top positive impacts were government responsiveness to change, followed by internal collaboration within companies:
|Rank||Factor||% Change (2020 vs. 3-Yr Avg)|
|1||Government's responsiveness to change||8.2%|
|2||Collaboration within a company||4.6%|
|3||Venture capital availability||4.4%|
|4||Social safety net protection||4.2%|
|5||Soundness of banks||4.0%|
Interestingly, internal collaboration improved while external collaboration got worse. This is likely because companies had to adapt to changing work environments, while also learning how to collaborate with one another through remote working.
Internal collaboration didn’t just improve in advanced economies. In fact, developing economies experienced several of the top positive impacts that advanced economies saw as well:
|Rank||Factor||% Change (2020 vs. 3-Yr Avg)|
|1||Collaboration within a company||6.9%|
|2||Government's responsiveness to change||6.8%|
|3||Efficiency of train transport services||5.9%|
|4||Venture capital availability||5.9%|
|5||Country capacity to attract talent||5.8%|
While perceptions on official responsiveness to change increased, public trust in politicians decreased slightly. This indicates that, while government responses to COVID-19 may have been received well in developing economies, overall feelings towards political leaders did not waiver.
How Have Countries Stayed Strong During the Pandemic?
While the impacts of COVID-19 varied between advanced and developing economies, business leaders across the board identified some common features that helped countries remain resilient:
- Economic digitization and digital skills
Social distancing has been a key response to the pandemic. Because of this, countries that were set up for remote work have fared better than others. Netherlands, New Zealand, and Finland are a few examples.
- Safety nets and financial soundness
Countries with established support systems for companies and citizens were in a better position to keep their economies afloat. Denmark and Norway provided much-needed support to their households, while Taiwan and the U.S. were able to aid businesses thanks to strong financial systems.
- Governance and planning
Balancing health priorities with economic and fiscal policies was a delicate dance this year. Countries that provided relatively stable political frameworks were Singapore, Luxembourg, Austria, and the United Arab Emirates.
- Healthcare system and R&D
A strong healthcare system meant widespread access to health services needed during the pandemic, as well as established public health protocols. Japan, Spain, and Taiwan were good examples of this.
Will these key features of competitiveness remain effective measures of a strong economy in 2021, or will our benchmarks for success evolve post-pandemic?
The Race to Save Lives: Comparing Vaccine Development Timelines
This graphic looks at how long vaccine development has historically taken for pandemics dating back to the 1900s.
The Race to Save Lives: Vaccine Development Timelines
View the high-resolution of the infographic by clicking here.
Major advancements in medicine have led to a significant increase in average life expectancy, with vaccines being hailed as one of the most successful interventions to date.
In fact, the World Health Organization estimates that vaccines have prevented 10 million deaths between 2010 and 2015 alone. But while some were created and distributed in just over four months, others have taken over 40 years to develop. Then again, previous pandemics have petered out without any vaccine at all.
With approved COVID-19 vaccines soon to be distributed across the globe, the vaccine development process is being scrutinized by experts (and non-experts) the world over.
In the graphic above, we explore how long it has historically taken to bring a vaccine to market during pandemics dating back to the 1900s, and what the process entails.
Pandemic Vaccines of the Past
Although the assumption can be made that developing a vaccine for infectious diseases has become more efficient since the 1900s, that statement is not entirely correct.
It took approximately 25 years to develop a vaccine for the Spanish Flu which killed between 40-50 million people. Similarly, it was only last year that the FDA approved the first Ebola vaccine—an effort that took 43 years since the discovery of the virus.
But while scientists and medical experts have made headway in stopping major pandemics in their tracks, some of the worst outbreaks in history have yet to be cured.
Here is a closer look at the timeframes for vaccine development for every pandemic since the turn of the 20th century:
|Name of Pandemic||Death Toll||Timeframe for Vaccine Development||Duration|
|Spanish flu||40-50 million||1917-1942||25 years|
|H2N2 Asian flu||1.1 million||Feb 1957-Jun 1957||<5 months|
|H3N2 Hong Kong Flu||1 million||Jul 1968-Nov 1968||<5 months|
|SARS||774 (ongoing)||2003-present||17 years (ongoing)|
|AIDS||25-35 million (ongoing)||1981-present||39 years (ongoing)|
|H1N1 Swine Flu||151,700 - 575,400||Apr 2009-Sept 2009||6 months|
|MERS||858 (ongoing)||2012-present||8 years (ongoing)|
|Coronavirus||1.64 million (ongoing)||Dec 2019-Nov 2020||11 months|
When it comes to the speedy development of a COVID-19 vaccine, funding has played a vital role. With case numbers growing at an alarming rate, demand and urgency for a vaccine are high. In the U.S., the government paid Pfizer and BioNTech almost $2 billion for 100 million doses of a safe vaccine for COVID-19. This level of support from governments the world over means that pharmaceutical giants have less financial uncertainties to deal with compared to other vaccines.
Even though the global endeavor to distribute COVID-19 vaccines is now underway, many experts are concerned that the pace of approval could compromise long-term safety—but there are rigorous steps a vaccine must first go through before it is approved.
The Journey of a Vaccine Candidate
On average, it takes 10 years to develop a vaccine. According to the CDC, there are six stages involved in the process from start to finish:
- Exploratory stage: This stage typically consists of basic lab research that can last anywhere from 2 to 4 years.
- Pre-clinical stage: This stage uses tissue-culture or cell-culture systems and animal testing to give researchers an idea of how humans might respond to a candidate vaccine.
- Clinical development: Within the clinical development stage, there are three phases. Phase 1 examines the response of a small group of people to a candidate vaccine. Phase 2 involves giving the candidate vaccine to a larger group of people to study its safety, immunogenicity, proposed doses, schedule of immunizations, and method of delivery. In Phase 3, the vaccine is given to thousands of people to further test for efficacy and safety.
- Regulatory review and approval: National Regulatory Authorities are responsible for the approval of vaccines in different countries. For example, the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) regulates all U.S. vaccines.
- Manufacturing: Typically, it can take anywhere from 6 to 36 months to produce, package, and deliver a high quality vaccine.
- Quality control: Different batches of a vaccine are continuously tested by different authorities around the world to ensure its ongoing safety.
Despite these lengthy timeframes, the COVID-19 vaccines and subsequent candidates have overturned the conventional process due to their unconventional technology.
Innovative Technologies Driving COVID’s Cure
Even though there are no approved vaccines for other coronaviruses such as MERS and SARS, previous research into these diseases has helped identify potential solutions for COVID-19 using messenger RNA (mRNA) technology.
“The mRNA vaccine platform technology [which the Pfizer/BioNTech vaccine uses] has been in development for over two decades.”
—Dr Zoltán Kis, Imperial College London.
The technology instructs our bodies to produce a small part of the COVID-19 virus called a spike protein. This triggers the immune system to make antibodies to fight against it and prepares the body for an actual COVID-19 infection.
Containing COVID-19 Batch-by-Batch
Deployment of a safe and effective vaccine could have the potential to save millions of lives and prevent infection for many more.
Although some experts have criticized the speed of vaccine candidate approvals, the quality will be closely monitored on a batch-by-batch basis.
With the COVID-19 crisis showing no signs of slowing down, most of us continue to live in hope that the light is at the end of the tunnel.
Technology2 months ago
50 Years of Gaming History, by Revenue Stream (1970-2020)
Markets1 month ago
The Year in Review: 2020 in 20 Visualizations
Technology4 weeks ago
Switch to Success: 20 Years of Nintendo Console Sales
Misc1 month ago
Chart: A Global Look at How People Spend Their Time
Markets2 weeks ago
Prediction Consensus: What the Experts See Coming in 2021
Misc3 weeks ago
Visualizing the U.S. Population by Race
Precious Metals3 weeks ago
How Every Asset Class, Currency, and S&P 500 Sector Performed in 2020
Technology3 weeks ago
Mapped: The Top Surveillance Cities Worldwide